T Scan Therapeutics, Inc. TCRX
We take great care to ensure that the data presented and summarized in this overview for TScan Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TCRX
View all-
Lynx1 Capital Management LP San Juan, PR5.22MShares$21.5 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$20.6 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$18.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$18.1 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$12.3 Million0.47% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$11.5 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.35MShares$9.67 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$8.6 Million6.03% of portfolio
-
Deer Management Co. LLC Larchmont, NY1.25MShares$5.13 Million1.01% of portfolio
-
Alphabet Inc. Mountain View, CA1.08MShares$4.44 Million0.37% of portfolio
Latest Institutional Activity in TCRX
Top Purchases
Top Sells
About TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Transactions at TCRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Lynx1 Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
947
+0.02%
|
$3,788
$4.34 P/Share
|
|
Sep 23
2024
|
Barbara Klencke |
BUY
Open market or private purchase
|
Direct |
5,000
+10.0%
|
$25,000
$5.29 P/Share
|
|
Aug 26
2024
|
Barbara Klencke |
BUY
Open market or private purchase
|
Direct |
5,000
+11.11%
|
$25,000
$5.53 P/Share
|
|
Aug 23
2024
|
Barbara Klencke |
BUY
Open market or private purchase
|
Direct |
5,000
+12.5%
|
$25,000
$5.69 P/Share
|
|
Aug 23
2024
|
Zoran Zdraveski |
SELL
Open market or private sale
|
Direct |
164,686
-97.22%
|
$823,430
$5.78 P/Share
|
|
Aug 23
2024
|
Zoran Zdraveski |
BUY
Exercise of conversion of derivative security
|
Direct |
157,186
+26.23%
|
$471,558
$3.11 P/Share
|
|
Dec 19
2023
|
Timothy J Barberich |
BUY
Open market or private purchase
|
Direct |
317
+0.47%
|
$1,268
$4.97 P/Share
|
|
Dec 18
2023
|
Timothy J Barberich |
BUY
Open market or private purchase
|
Direct |
28,830
+30.18%
|
$115,320
$4.89 P/Share
|
|
Dec 14
2023
|
Barbara Klencke |
BUY
Open market or private purchase
|
Direct |
5,000
+14.29%
|
$25,000
$5.08 P/Share
|
|
Jun 02
2023
|
Timothy J Barberich |
BUY
Open market or private purchase
|
Direct |
37,880
+50.0%
|
$75,760
$2.63 P/Share
|
|
May 31
2023
|
Lynx1 Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,400
-0.15%
|
$30,800
$2.52 P/Share
|
|
May 31
2023
|
Lynx1 Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.19%
|
$20,000
$2.51 P/Share
|
|
Dec 28
2022
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,158
+8.76%
|
$3,158
$1.56 P/Share
|
|
Dec 27
2022
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,842
+8.73%
|
$2,842
$1.5 P/Share
|
|
May 18
2022
|
David P Southwell Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+7.0%
|
$75,000
$3.59 P/Share
|
|
May 11
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
25,865
+1.01%
|
$25,865
$1.99 P/Share
|
|
May 10
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1,333,927
+16.98%
|
$1,333,927
$1.86 P/Share
|
|
Mar 24
2022
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+35.81%
|
$45,000
$3.4 P/Share
|
|
Dec 23
2021
|
David P Southwell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,670
+24.93%
|
$48,670
$1.97 P/Share
|
|
Sep 23
2021
|
Zoran Zdraveski |
BUY
Open market or private purchase
|
Direct |
4,716
+50.0%
|
$33,012
$7.48 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 50.1K shares |
|---|---|
| Exercise of conversion of derivative security | 157K shares |
| Open market or private sale | 165K shares |
|---|